I
I-MAB D
D
IMAB
1.05000
USD
-0.01
(-0.94%)
مغلق
حجم التداول
4,981
الربح لكل سهم
-0
العائد الربحي
-
P/E
-2
حجم السوق
85,743,363
الأخبار المقالات
العنوان: I/MAB
القطاع: Healthcare
الصناعة: Biotechnology
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).